Evolving character of chronic central nervous system HIV infection

Seminars in Neurology

Volumn 34, Issue 1, 2014, Pages 7-13

  Price, Richard W ^a   Spudich, Serena S ^b   Peterson, Julia ^a   Joseph, Sarah ^c,f   Fuchs, Dietmar ^d   Zetterberg, Henrik ^e   Gisslén, Magnus ^e   Swanstrom, Ronald ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; brain; cerebrospinal fluid; dementia; HIV; inflammation; treatment

Indexed keywords

BIOLOGICAL MARKER;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; DISEASE COURSE; GENETIC TRAIT; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNE SYSTEM; MORPHOLOGICAL TRAIT; PATHOGENESIS; PRIMARY INFECTION; PRIORITY JOURNAL; CENTRAL NERVOUS SYSTEM INFECTIONS; CHRONIC DISEASE; COMPLICATION; HIV INFECTIONS; VIROLOGY;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM INFECTIONS; CHRONIC DISEASE; HIV INFECTIONS; HUMANS;

EID: 84898457466     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1372337     Document Type: Article

References (47)

1. Davis L. E., Hjelle B. L., Miller V. E., et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology: 1992; 42 9 1736 1739
2. Spudich S., Gisslen M., Hagberg L., et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis: 2011; 204 5 753 760
3. Valcour V., Chalermchai T., Sailasuta N., et al. RV254/SEARCH 010 Study Group. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis: 2012; 206 2 275 282
4. Ellis R. J., Hsia K., Spector S. A., et al. HIV Neurobehavioral Research Center Group. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol: 1997; 42 5 679 688 (Pubitemid 27481539)
5. Spudich S. S., Nilsson A. C., Lollo N. D., et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis: 2005; 5 98
6. Price R. W., Brew B., Sidtis J., Rosenblum M., Scheck A. C., Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science: 1988; 239 4840 586 592 (Pubitemid 18066218)
7. Price R. W., Peterson J., Fuchs D., et al. Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol: 2013; 8 5 1147 1158
8. Deeks S. G., Tracy R., Douek D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity: 2013; 39 4 633 645
9. Spudich S., González-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med: 2012; 2 6 a007120
10. Burdo T. H., Lackner A., Williams K. C. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev: 2013; 254 1 102 113
11. Navia B. A., Jordan B. D., Price R. W. The AIDS dementia complex: I. Clinical features. Ann Neurol: 1986; 19 6 517 524 (Pubitemid 16085185)
12. Hunt P. W. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep: 2012; 9 2 139 147
13. El-Sadr W. M., Lundgren J., Neaton J. D., et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med: 2006; 355 22 2283 2296 (Pubitemid 44837777)
14. El-Sadr W. M., Grund B., Neuhaus J., et al. SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med: 2008; 149 5 289 299
15. Phillips A. N., Neaton J., Lundgren J. D. The role of HIV in serious diseases other than AIDS. AIDS: 2008; 22 18 2409 2418
16. Mellors J. W., Muñoz A., Giorgi J. V., et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med: 1997; 126 12 946 954 (Pubitemid 27255797)
17. Lyles R. H., Tang A. M., Smit E., et al. Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr: 1999; 22 4 386 394 (Pubitemid 30030431)
18. Giorgi J. V., Lyles R. H., Matud J. L., et al. Multicenter AIDS Cohort Study. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr: 2002; 29 4 346 355 (Pubitemid 34288887)
19. Neaton J. D., Neuhaus J., Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS: 2010; 5 6 480 490
20. Shacklett B. L., Cox C. A., Wilkens D. T., et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis: 2004; 189 12 2202 2212 (Pubitemid 38757192)
21. Sadagopal S., Lorey S. L., Barnett L., et al. Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol: 2008; 82 21 10418 10428 (Pubitemid 352691154)
22. Ho E. L., Ronquillo R., Altmeppen H., Spudich S. S., Price R. W., Sinclair E. Cellular composition of cerebrospinal fluid in HIV-1 infected and uninfected subjects. PLoS ONE: 2013; 8 6 e66188
23. Hagberg L., Cinque P., Gisslen M., et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther: 2010; 7 15
24. Yilmaz A., Yiannoutsos C. T., Fuchs D., et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation: 2013; 10 62
25. Abdulle S., Mellgren A., Brew B. J., et al. CSF neurofilament protein (NFL)-a marker of active HIV-related neurodegeneration. J Neurol: 2007; 254 8 1026 1032 (Pubitemid 47353414)
26. Peluso M. J., Meyerhoff D. J., Price R. W., et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis: 2013; 207 11 1703 1712
27. Antinori A., Arendt G., Becker J. T., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology: 2007; 69 18 1789 1799 (Pubitemid 350059308)
28. Schnell G., Spudich S., Harrington P., Price R. W., Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog: 2009; 5 4 e1000395
29. Schnell G., Joseph S., Spudich S., Price R. W., Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog: 2011; 7 10 e1002286
30. Arrildt K. T., Joseph S. B., Swanstrom R. The HIV-1 env protein: a coat of many colors. Curr HIV/AIDS Rep: 2012; 9 1 52 63
31. González-Scarano F., Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol: 2005; 5 1 69 81 (Pubitemid 40070332)
32. Weiser B., Philpott S., Klimkait T., et al. Swiss HIV Cohort Study. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS: 2008; 22 4 469 479 (Pubitemid 351317288)
33. Spudich S. S., Huang W., Nilsson A. C., et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis: 2005; 191 6 890 898 (Pubitemid 40349804)
34. Staprans S., Marlowe N., Glidden D., et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS: 1999; 13 9 1051 1061 (Pubitemid 29361395)
35. Ellis R. J., Gamst A. C., Capparelli E., et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology: 2000; 54 4 927 936 (Pubitemid 30111354)
36. Spudich S., Price R. W. Neurologic disease. In: Dolin R., Masur H., Saag M. S., eds. AIDS therapy. 3rd ed. Philadelphia, PA Churchill Livingston Elsevier: 2008; 1075 1101
37. Brew B. J., Bhalla R. B., Paul M., et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS: 1992; 6 5 461 465
38. Gisslén M., Rosengren L., Hagberg L., Deeks S. G., Price R. W. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther: 2005; 2 6
39. Gisslen M., Hagberg L., Rosengren L., et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol: 2007; 2 1 112 119
40. Letendre S., Marquie-Beck J., Capparelli E., et al. CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol: 2008; 65 1 65 70
41. Yilmaz A., Price R. W., Gisslén M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother: 2012; 67 2 299 311
42. Dennis A. M., Napravnik S., Seña A. C., Eron J. J. Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis: 2011; 53 5 480 487
43. Likatavicius G., Van de Laar M. HIV and AIDS in the European Union, 2011. Euro Surveill: 2012; 17 48 20329
44. Edén A., Fuchs D., Hagberg L., et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis: 2010; 202 12 1819 1825
45. Canestri A., Lescure F. X., Jaureguiberry S., et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis: 2010; 50 5 773 778
46. Peluso M. J., Ferretti F., Peterson J., et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS: 2012; 26 14 1765 1774
47. Price R. W., Epstein L. G., Becker J. T., et al. Biomarkers of HIV-1 CNS infection and injury. Neurology: 2007; 69 18 1781 1788 (Pubitemid 350059307)